Cargando…

Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study

OBJECTIVE: Camrelizumab is a newly developed program-death receptor one inhibitor; the real-world evidence about its application in hepatocellular carcinoma (HCC) treatment is lacking. Therefore, this prospective, multi-center, real-world study evaluated the efficacy and safety of camrelizumab plus...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Ran, Xu, Qingyu, Wang, Qi, Zhang, Qingqiao, Zhou, Weizhong, Cao, Chi, Huang, Xiangzhong, Ji, Honghai, Lv, Penghua, Jiang, Hao, Lu, You, Jin, Yong, Li, Yongjun, Cheng, Long, Wang, Weidong, Xu, Hao, Zhu, Xiaoli, Yin, Guowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378838/
https://www.ncbi.nlm.nih.gov/pubmed/35982962
http://dx.doi.org/10.3389/fonc.2022.816198
_version_ 1784768597013299200
author You, Ran
Xu, Qingyu
Wang, Qi
Zhang, Qingqiao
Zhou, Weizhong
Cao, Chi
Huang, Xiangzhong
Ji, Honghai
Lv, Penghua
Jiang, Hao
Lu, You
Jin, Yong
Li, Yongjun
Cheng, Long
Wang, Weidong
Xu, Hao
Zhu, Xiaoli
Yin, Guowen
author_facet You, Ran
Xu, Qingyu
Wang, Qi
Zhang, Qingqiao
Zhou, Weizhong
Cao, Chi
Huang, Xiangzhong
Ji, Honghai
Lv, Penghua
Jiang, Hao
Lu, You
Jin, Yong
Li, Yongjun
Cheng, Long
Wang, Weidong
Xu, Hao
Zhu, Xiaoli
Yin, Guowen
author_sort You, Ran
collection PubMed
description OBJECTIVE: Camrelizumab is a newly developed program-death receptor one inhibitor; the real-world evidence about its application in hepatocellular carcinoma (HCC) treatment is lacking. Therefore, this prospective, multi-center, real-world study evaluated the efficacy and safety of camrelizumab plus transarterial chemoembolization (TACE) in treating intermediate-to-advanced HCC patients. METHODS: This study consecutively enrolled 101 intermediate to advanced HCC patients. All patients received camrelizumab-based treatment within 30 days of the perioperative period of the TACE operation. The primary outcome was progression-free survival (PFS), and the secondary effects were overall survival (OS), objective response rate (ORR), disease control rate (DCR), and AEs. RESULTS: Specifically, the median PFS was 9.7 (95% confidence interval: 7.4–12.0) months, with a 1-year PFS rate of 30.6%. Meanwhile, the median OS was not reached (NR) yet, with a 1-year OS rate of 61.9%. Besides, the CR, PR, SD, and PD rates were 12.8%, 44.9%, 29.5%, and 12.8%, respectively. The ORR and DCR were 57.7% and 87.2%, respectively. More cycles of camrelizumab were independently correlated with prolonged PFS (hazard ratio (HR): 0.415, P = 0.002), whereas longer intervals between camrelizumab administration and TACE were independently associated with unfavorable PFS (HR: 1.873, P = 0.032). The incidence of total AEs was 90.1%; most AEs were grade 1 (20.8%), grade 2 (28.7%) and grade 3 (37.6%), while only 3 (3.0%) patients had grade 4 AEs. CONCLUSION: The camrelizumab plus TACE regimen is effective and safe, indicating its potential to serve as a promising treatment choice for intermediate to advanced HCC patients.
format Online
Article
Text
id pubmed-9378838
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93788382022-08-17 Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study You, Ran Xu, Qingyu Wang, Qi Zhang, Qingqiao Zhou, Weizhong Cao, Chi Huang, Xiangzhong Ji, Honghai Lv, Penghua Jiang, Hao Lu, You Jin, Yong Li, Yongjun Cheng, Long Wang, Weidong Xu, Hao Zhu, Xiaoli Yin, Guowen Front Oncol Oncology OBJECTIVE: Camrelizumab is a newly developed program-death receptor one inhibitor; the real-world evidence about its application in hepatocellular carcinoma (HCC) treatment is lacking. Therefore, this prospective, multi-center, real-world study evaluated the efficacy and safety of camrelizumab plus transarterial chemoembolization (TACE) in treating intermediate-to-advanced HCC patients. METHODS: This study consecutively enrolled 101 intermediate to advanced HCC patients. All patients received camrelizumab-based treatment within 30 days of the perioperative period of the TACE operation. The primary outcome was progression-free survival (PFS), and the secondary effects were overall survival (OS), objective response rate (ORR), disease control rate (DCR), and AEs. RESULTS: Specifically, the median PFS was 9.7 (95% confidence interval: 7.4–12.0) months, with a 1-year PFS rate of 30.6%. Meanwhile, the median OS was not reached (NR) yet, with a 1-year OS rate of 61.9%. Besides, the CR, PR, SD, and PD rates were 12.8%, 44.9%, 29.5%, and 12.8%, respectively. The ORR and DCR were 57.7% and 87.2%, respectively. More cycles of camrelizumab were independently correlated with prolonged PFS (hazard ratio (HR): 0.415, P = 0.002), whereas longer intervals between camrelizumab administration and TACE were independently associated with unfavorable PFS (HR: 1.873, P = 0.032). The incidence of total AEs was 90.1%; most AEs were grade 1 (20.8%), grade 2 (28.7%) and grade 3 (37.6%), while only 3 (3.0%) patients had grade 4 AEs. CONCLUSION: The camrelizumab plus TACE regimen is effective and safe, indicating its potential to serve as a promising treatment choice for intermediate to advanced HCC patients. Frontiers Media S.A. 2022-08-02 /pmc/articles/PMC9378838/ /pubmed/35982962 http://dx.doi.org/10.3389/fonc.2022.816198 Text en Copyright © 2022 You, Xu, Wang, Zhang, Zhou, Cao, Huang, Ji, Lv, Jiang, Lu, Jin, Li, Cheng, Wang, Xu, Zhu and Yin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
You, Ran
Xu, Qingyu
Wang, Qi
Zhang, Qingqiao
Zhou, Weizhong
Cao, Chi
Huang, Xiangzhong
Ji, Honghai
Lv, Penghua
Jiang, Hao
Lu, You
Jin, Yong
Li, Yongjun
Cheng, Long
Wang, Weidong
Xu, Hao
Zhu, Xiaoli
Yin, Guowen
Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study
title Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study
title_full Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study
title_fullStr Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study
title_full_unstemmed Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study
title_short Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study
title_sort efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: a prospective, multi-center, real-world study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378838/
https://www.ncbi.nlm.nih.gov/pubmed/35982962
http://dx.doi.org/10.3389/fonc.2022.816198
work_keys_str_mv AT youran efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT xuqingyu efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT wangqi efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT zhangqingqiao efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT zhouweizhong efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT caochi efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT huangxiangzhong efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT jihonghai efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT lvpenghua efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT jianghao efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT luyou efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT jinyong efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT liyongjun efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT chenglong efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT wangweidong efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT xuhao efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT zhuxiaoli efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy
AT yinguowen efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy